Telmisartan Versus Ramipril After Acute Coronary Syndrome

Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome

The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome

Inclusion Criteria:

• Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,
• presence of ECG ischemic changes,
• angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography,
• successful coronary revascularization of at least one culprit coronary vessel.

Exclusion Criteria:

• Age>80 years, current ACE inhibitor or ARB treatment,
• ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand,
• ECG abnormalities that could affect the recognition of ST segment shift,
• recent or chronic infective or inflammatory diseases,
• malignancy, and myocardial infarction,
• surgery or trauma in the previous month.